MX2022011291A - Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. - Google Patents
Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.Info
- Publication number
- MX2022011291A MX2022011291A MX2022011291A MX2022011291A MX2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A
- Authority
- MX
- Mexico
- Prior art keywords
- gram
- treatment
- new
- bacterial infections
- negative bacterial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382177 | 2020-03-11 | ||
| EP20382254 | 2020-03-31 | ||
| PCT/EP2021/056264 WO2021180892A1 (en) | 2020-03-11 | 2021-03-11 | New recombinant lysin and its use in the treatment of gram-negative bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011291A true MX2022011291A (es) | 2022-12-08 |
Family
ID=74859480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011291A MX2022011291A (es) | 2020-03-11 | 2021-03-11 | Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12655409B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4118192A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7863509B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115605587B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021236351A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175024A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011291A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021180892A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023139605A1 (en) * | 2022-01-20 | 2023-07-27 | Techinvention Lifecare Pvt. Ltd. | Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria |
| CN114774391B (zh) * | 2022-03-09 | 2023-03-14 | 华南农业大学 | 一种抗大肠杆菌的噬菌体内溶素及其应用 |
| WO2024231498A1 (en) * | 2023-05-09 | 2024-11-14 | BioNTech SE | Intravaginal formulations of gardnerella endolysins |
| FR3149209B1 (fr) * | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| WO2024246325A1 (en) * | 2023-06-02 | 2024-12-05 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| CN121420063A (zh) * | 2023-06-30 | 2026-01-27 | 国立大学法人 冈山大学 | 可穿透革兰氏阴性菌外膜的多肽、包含所述多肽的抗菌蛋白、抗菌剂或消毒剂、药物组合物、以及抗菌剂组合物或消毒剂组合物 |
| TW202541833A (zh) * | 2023-12-12 | 2025-11-01 | 德商拜恩技術股份公司 | 包含內溶素之組合物及其用途 |
| CN118420716B (zh) * | 2024-05-28 | 2025-10-31 | 青岛农业大学 | 一种多肽125、包含多肽125的生物材料及应用 |
| WO2026139534A1 (en) * | 2024-12-24 | 2026-07-02 | Telum Therapeutics, S.L. | Antibacterial peptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010002959A2 (en) * | 2008-07-03 | 2010-01-07 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| PL2445515T3 (pl) | 2009-06-26 | 2016-10-31 | Środki przeciwdrobnoustrojowe | |
| JP5847081B2 (ja) | 2009-08-24 | 2016-01-20 | カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー | エンドリシンOBPgpLYS |
| RU2614114C2 (ru) | 2010-09-17 | 2017-03-22 | Текнифар-Индустриа Текника Фармасьютика, С.А | Бактериофаги, фаговые пептиды и способы их применения |
| GB201018518D0 (en) | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| EP2468856A1 (en) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| BR112016030580B1 (pt) | 2014-06-26 | 2023-12-19 | The Rockefeller University | Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas |
| ES2934714T3 (es) | 2015-09-17 | 2023-02-24 | Contrafect Corp | Polipéptidos de lisina activos contra bacterias Gram-negativas |
| KR20240162610A (ko) * | 2017-04-03 | 2024-11-15 | 사시나파스 컴퍼니 리미티드 | 조작된 그람-음성 엔도리신 |
| CN111420037B (zh) * | 2020-03-26 | 2022-05-10 | 中国农业科学院饲料研究所 | 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用 |
-
2021
- 2021-03-11 WO PCT/EP2021/056264 patent/WO2021180892A1/en not_active Ceased
- 2021-03-11 MX MX2022011291A patent/MX2022011291A/es unknown
- 2021-03-11 US US17/910,688 patent/US12655409B2/en active Active
- 2021-03-11 AU AU2021236351A patent/AU2021236351A1/en active Pending
- 2021-03-11 EP EP21710319.1A patent/EP4118192A1/en active Pending
- 2021-03-11 CN CN202180034907.8A patent/CN115605587B/zh active Active
- 2021-03-11 CN CN202511878710.9A patent/CN121422198A/zh active Pending
- 2021-03-11 JP JP2022554850A patent/JP7863509B2/ja active Active
- 2021-03-11 CA CA3175024A patent/CA3175024A1/en active Pending
-
2025
- 2025-11-17 US US19/391,852 patent/US20260226444A1/en active Pending
- 2025-12-04 JP JP2025231925A patent/JP2026041893A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260226444A1 (en) | 2026-08-06 |
| JP2023517245A (ja) | 2023-04-24 |
| JP2026041893A (ja) | 2026-03-10 |
| US12655409B2 (en) | 2026-06-16 |
| WO2021180892A1 (en) | 2021-09-16 |
| CN115605587A (zh) | 2023-01-13 |
| CN115605587B (zh) | 2026-02-13 |
| JP7863509B2 (ja) | 2026-05-21 |
| AU2021236351A1 (en) | 2022-10-06 |
| US20230138922A1 (en) | 2023-05-04 |
| EP4118192A1 (en) | 2023-01-18 |
| CN121422198A (zh) | 2026-01-30 |
| CA3175024A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500360A1 (en) | Antibiotic compounds | |
| Chessa et al. | An overview of Staphylococcus epidermidis and Staphylococcus aureus with a focus on developing countries | |
| JP2018509415A5 (cg-RX-API-DMAC7.html) | ||
| ZA202002093B (en) | Antibacterial compounds | |
| EP2046287A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING INFECTIONS | |
| SA521430976B1 (ar) | مضادات حيوية كبيرة الحلقة واسعة المدى | |
| PH12019501904A1 (en) | Macrocyclic broad spectrum antibiotics | |
| WO2021247965A3 (en) | Novel peptide inhibitors against beta-lactam resistance in bacteria | |
| WO2021081110A3 (en) | Peptides and use thereof | |
| WO2020232471A3 (en) | Methods and compositions comprising staphylococcus protein a (spa) variants | |
| MXPA06000691A (es) | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas. | |
| ATE510845T1 (de) | Antibakterielle makrozyklen mit substituiertem biphenyl | |
| Spanik et al. | Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis | |
| AR073917A1 (es) | Sinergismo antibiotico | |
| WO2018140707A8 (en) | Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces | |
| TW200716162A (en) | Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria | |
| WO2005021575A3 (en) | Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties | |
| MX2023012943A (es) | Compuesto antibacteriano. | |
| EP4487917A3 (en) | Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances | |
| MX2021012375A (es) | Metodo para tratar y prevenir infecciones oseas y de articulaciones. | |
| Gaya et al. | Comparative in vitro activity of cefuroxime and its interactions with aminoglycoside antibiotics | |
| CL2025001925A1 (es) | Polipéptido antimicrobiano micropacina k2, composición que lo comprende y uso para tratar infecciones bacterianas | |
| Hashim et al. | The role of antibiotic resistance mobile genetic element MCR-1 in enhancing bacterial survival in macrophages | |
| WO2025186334A8 (en) | Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity | |
| MX2019001280A (es) | NUEVAS COMPOSICIONES FARMACEUTICAS CON UN PEPTIDO DE FUSION DE LA BETA-DEFENSINA MODIFICADA HßD3-M Y ANTIBIOTICOS COMERCIALES PARA SU USO EN EL TRATAMIENTO DE INFECCIONES CON BACTERIAS PATOGENAS. |